IART
Integra Lifesciences Holdings Corp is engaged in development, manufacturing, and marketing of product lines from its technology for applications ranging from burn and deep tissue wounds to repair of dura mater in the brain to repair of nerve and tendon.
Integra LifeSciences Holdings Corporation (IART) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (C-). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C (2.4) | C- (1.9) | B- (3.1) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-05 | C (2.4) | C- (1.9) | B- (3.1) | C+ (2.6) | C+ (2.7) | C+ (2.5) |
| 2026-10-29 | C+ (2.5) | C- (1.9) | B- (3.1) | B- (3.0) | C+ (2.7) | C+ (2.6) |
| 2026-10-22 | C+ (2.6) | C- (1.9) | B (3.2) | C+ (2.6) | C+ (2.6) | C+ (2.6) |
| 2026-10-15 | B (3.3) | C- (1.9) | B (3.2) | C+ (2.7) | C+ (2.6) | C+ (2.7) |